<?xml version="1.0" encoding="UTF-8"?>
<p>Anakinra has been approved by the FDA for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease. It is a recombinant human interleukin-1 receptor antagonist (IL-1Ra), and it is currently being tested in ongoing trials with COVID-19 patients to contrast the uncontrolled inflammatory response. In one retrospective study of 29 patients with COVID-19, those that received high-dose of Anakinra in combination with standard treatment had a faster respiratory improvement compared to 16 patients who received standard therapy alone (72 and 50%, respectively) (
 <xref rid="B97" ref-type="bibr">97</xref>).
</p>
